Who are Q/C Technologies, Inc.'s main suppliers?

Q/C Technologies, Inc. (QCLS) key suppliers include: LIGHTSOLVER-LTD, LPU-HOLDINGS-LLC, PHARMACYTE, CHELSEA-VOSS, OCEAN-AVENUE-HOLDINGS-LLC and 1 more. View the full supplier network at chainsifter.com/chain/QCLS.

Who are Q/C Technologies, Inc.'s major customers?

Q/C Technologies, Inc. (QCLS) key customers include: LIGHTSOLVER-LTD, LPU-HOLDINGS-LLC. View the full customer network at chainsifter.com/chain/QCLS.

What sector is Q/C Technologies, Inc. in?

Q/C Technologies, Inc. (QCLS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

QCLS Supply Chain: Q/C Technologies, Inc. Supplier List & 10 Relationships

6Suppliers

2Customers

2Debt Items

3Related Chains

Q/C Technologies, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LIGHTSOLVER-LTD	LIGHTSOLVER-LTD	92%	The Company’s relationship with LightSolver provides access to licensed technology that emphasizes the development of LPUs, including the qc-LPU100.
LPU-HOLDINGS-LLC	LPU-HOLDINGS-LLC	92%	the Company agreed to acquire 100% of the membership interests of LPU Holdings LLC from the Sellers
PHARMACYTE	PHARMACYTE	92%	the Company entered into that certain securities purchase agreement with certain accredited investors, including Pharmacyte, pursuant to which it agreed to sell to Pharmacyte an aggregate of 3,000 sh…
CHELSEA-VOSS	CHELSEA-VOSS	90%	Ms. Voss agreed to provide certain consulting services to the Company
OCEAN-AVENUE-HOLDINGS-LLC	OCEAN-AVENUE-HOLDINGS-LLC	90%	Ocean Avenue Holdings agreed to provide certain consulting services to the Company
PREMAS-BIOTECH-PVT-LTD	PREMAS-BIOTECH-PVT-LTD	90%	The Company previously owned, through its former subsidiary Cystron Biotech, LLC (“Cystron”), an exclusive license from Premas Biotech PVT Ltd. (“Premas”) with respect to Premas’ vaccine platform for…

Q/C Technologies, Inc. Customers

Ticker	Name	Confidence	Evidence
LIGHTSOLVER-LTD	LIGHTSOLVER-LTD	85%	laser-based computing system ● our ability to realize value from our legacy pharmaceutical assets, including Isomyosamine (formerly named MYMD-1) and Supera-CBD; ● challenges we may face with maintai…
LPU-HOLDINGS-LLC	LPU-HOLDINGS-LLC	85%	terms of the agreement, the counterparty assigned its rights and interest in certain patents to the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as …

Q/C Technologies, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
QCLS-DEBT-11976	Warrants outstanding: 61333	90%	xbrl warrant detail from xbrl 2024-12-31.
QCLS-DEBT-11977	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.

Q/C Technologies, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Q/C Technologies, Inc..

Q/C Technologies, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Q/C Technologies, Inc..

Q/C Technologies, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MIRA	MIRA Pharmaceuticals, Inc.	38.88	1	['receiving']
PMCB	PharmaCyte Biotech, Inc.	38.88	1	['receiving']
CNBX	CNBX Pharmaceuticals Inc.	14.78	2

Q/C Technologies, Inc. Supply Chain